Combination therapies are the standard treatment for many forms of cancer including ovarian cancer, first-line breast cancer, prostate cancer and lung cancer.
XR-19 enables the joint encapsulation of two active pharmaceutical ingredients in one micelle. Oasmia believes XR-19 may help some compounds to be delivered in a single intravenous administration instead of two infusions, benefiting both patients and healthcare providers. Proof-of-concept and pre-clinical studies have shown promising results. Oasmia is evaluating the potential of various combinations for future development.